Antihypertensive therapy with indapamide and perindopril reduced mortality in patients >=80 years
Year: 2008
Type: article
Abstract: Antihypertensive therapy with indapamide and perindopril reduced mortality in patients >80 years STUDY DESIGN Design: randomised placebo controlled trial (Hypertension in the Very Elderly Trial [HYVET]).Allocation concealment: {concealed}*.À Blinding: blinded (patients, clinicians, and outcome adjudication committee).À STUDY QUESTION Setting: 195 centres in Europe, China, Australasia, and Tunisia.Patients: 3845 patients >80 years of age (mean age 84 y, 60% women) with persistent hypertension (mean sitting blood pressure [BP] 173/91 mm Hg).Exclusion criteria included accelerated or secondary hypertension, haemorrhagic stroke in the past 6 months, heart failure, gout, and dementia.Intervention: sustained-release indapamide, 1.5 mg/day, with perindopril, 2 or 4 mg/day, added if needed to reach targets of systolic BP ,150 mm Hg and diastolic BP ,80 mm Hg (n = 1933) or placebo (n = 1912).Outcomes: stroke, heart failure, any cardiovascular event, and death from any cause, cardiovascular cause, cardiac cause, or stroke.Follow-up period: median 1.8 years.Patient follow-up: 99.6% (intention-to-treat analysis). MAIN RESULTSAntihypertensive treatment reduced risks of heart failure, any cardiovascular event, and death from stroke or any cause (table).At 2 years, target BP was achieved by 48% of the antihypertensive treatment group and 20% of the placebo group. CONCLUSIONIn patients >80 years of age with persistent hypertension, antihypertensive therapy with indapamide and perindopril reduced all-cause mortality.
Source: BMJ Evidence-Based Medicine
DOI: 10.1136/ebm.13.5.136
Authors: W. W Hung, R. M Leipzig
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2500048525